Search

Your search keyword '"Odin, Joseph"' showing total 282 results

Search Constraints

Start Over You searched for: Author "Odin, Joseph" Remove constraint Author: "Odin, Joseph"
282 results on '"Odin, Joseph"'

Search Results

1. Investigation of the Role of Chemical Analysis in Causality Assessment of Herbal and Dietary Supplement-Induced Liver Injury

2. Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate

4. Drug-Induced Liver Injury in Pregnancy

6. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

7. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

8. Clinical characteristics and HLA associations of azithromycin‐induced liver injury.

10. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury

13. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

18. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

20. Contributors for Volume 2

23. Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES

25. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

31. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

39. Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature

41. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

46. Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

48. 686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY

Catalog

Books, media, physical & digital resources